688428 诺诚健华
交易中 03-06 10:09:52
资讯
新帖
简况
诺诚健华：首个自主研发的B7H3靶向ADC候选药正在入组患者
每日经济新闻 · 03-03 19:30
诺诚健华：首个自主研发的B7H3靶向ADC候选药正在入组患者
3月3日诺诚健华跌5.51%，富国精准医疗混合A基金重仓该股
证券之星 · 03-03 16:38
3月3日诺诚健华跌5.51%，富国精准医疗混合A基金重仓该股
诺诚健华新一代TRK抑制剂Zurletrectinib获中国优先审评资格 将用于儿童实体瘤治疗
美股速递 · 03-02
诺诚健华新一代TRK抑制剂Zurletrectinib获中国优先审评资格 将用于儿童实体瘤治疗
港股异动 | 诺诚健华(09969)尾盘涨超4% BCL2抑制剂联合奥布替尼3期临床完成患者入组
智通财经 · 02-27
港股异动 | 诺诚健华(09969)尾盘涨超4% BCL2抑制剂联合奥布替尼3期临床完成患者入组
诺诚健华新型BCL2抑制剂Mesutoclax联合奥布替尼一线治疗CLL/SLL的注册性III期临床试验完成患者入组
人民财讯 · 02-26
诺诚健华新型BCL2抑制剂Mesutoclax联合奥布替尼一线治疗CLL/SLL的注册性III期临床试验完成患者入组
诺诚健华宣布新型Tyk2抑制剂索菲西替尼在华治疗慢性自发性荨麻疹II/III期临床试验完成首例患者给药
美股速递 · 02-13
诺诚健华宣布新型Tyk2抑制剂索菲西替尼在华治疗慢性自发性荨麻疹II/III期临床试验完成首例患者给药
诺诚健华携手清华大学获批北京重点实验室
中国网财经 · 02-12
诺诚健华携手清华大学获批北京重点实验室
每周股票复盘：诺诚健华（688428）1月31日股本无变动
证券之星 · 02-08
每周股票复盘：诺诚健华（688428）1月31日股本无变动
2月6日诺诚健华涨10.13%，富国精准医疗混合A基金重仓该股
证券之星 · 02-06
2月6日诺诚健华涨10.13%，富国精准医疗混合A基金重仓该股
港股异动 | 诺诚健华(09969)早盘涨超4% 公司首次实现扭亏为盈 核心产品奥布替尼贡献显著增量
智通财经 · 02-05
港股异动 | 诺诚健华(09969)早盘涨超4% 公司首次实现扭亏为盈 核心产品奥布替尼贡献显著增量
诺诚健华（688428）披露证券变动月报表，2月4日股价上涨1.8%
证券之星 · 02-04
诺诚健华（688428）披露证券变动月报表，2月4日股价上涨1.8%
诺诚健华：公司预计2025年度首次实现扭亏为盈
证券日报 · 02-04
诺诚健华：公司预计2025年度首次实现扭亏为盈
诺诚健华新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验完成患者入组
每日经济新闻 · 02-02
诺诚健华新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验完成患者入组
每周股票复盘：诺诚健华（688428）预计2025年净利6.33亿
证券之星 · 02-01
每周股票复盘：诺诚健华（688428）预计2025年净利6.33亿
诺诚健华(09969.HK)高开逾13%
每日经济新闻 · 01-30
诺诚健华(09969.HK)高开逾13%
股市必读：诺诚健华（688428）预计2025年全年扣非后净利润盈利约5.34亿元
中金财经 · 01-30
股市必读：诺诚健华（688428）预计2025年全年扣非后净利润盈利约5.34亿元
诺诚健华（688428）披露2025年年度业绩预告，1月29日股价下跌1.18%
证券之星 · 01-29
诺诚健华（688428）披露2025年年度业绩预告，1月29日股价下跌1.18%
诺诚健华：公司未来会持续推进全球化战略
证券日报 · 01-29
诺诚健华：公司未来会持续推进全球化战略
诺诚健华：二级市场股价受多种因素影响
证券日报 · 01-29
诺诚健华：二级市场股价受多种因素影响
诺诚健华：预计2025年年度净利润6.33亿元 同比扭亏为盈
每日经济新闻 · 01-29
诺诚健华：预计2025年年度净利润6.33亿元 同比扭亏为盈
公司概况
公司名称：
诺诚健华医药有限公司
所属行业：
医药制造业
上市日期：
2022-09-21
主营业务：
诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼、坦昔妥单抗、ICP-248、ICP-B02。公司2023年被认定为国家级专精特新“小巨人”企业。
发行价格：
11.03
{"stockData":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":22.62,"timestamp":1772762992000,"preClose":21.78,"halted":0,"volume":2827965,"delay":0,"changeRate":0.0386,"floatShares":268000000,"shares":1764999999,"eps":-0.1302,"marketStatus":"交易中","change":0.84,"latestTime":"03-06 10:09:52","open":21.61,"high":22.73,"low":21.5,"amount":62763300,"amplitude":0.0565,"askPrice":22.63,"askSize":4,"bidPrice":22.62,"bidSize":8,"shortable":0,"etf":0,"ttmEps":-0.1302,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1772767800000},"marketStatusCode":2,"adr":0,"adjPreClose":21.78,"symbolType":"stock_kcb","openAndCloseTimeList":[[1772760600000,1772767800000],[1772773200000,1772780400000]],"highLimit":23.96,"lowLimit":19.6,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1764643952,"isCdr":false,"pbRate":5.77,"roa":"--","roe":"--","epsLYR":-0.26,"committee":-0.482456,"marketValue":39916000000,"turnoverRate":0.0105,"status":0,"hkstockBrief":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":11.63,"timestamp":1772762991311,"preClose":11.22,"halted":0,"volume":1012000,"delay":0,"premium":"-54.58"},"floatMarketCap":6070000000},"requestUrl":"/m/hq/s/688428/wiki","defaultTab":"wiki","newsList":[{"id":"2616370344","title":"诺诚健华：首个自主研发的B7H3靶向ADC候选药正在入组患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2616370344","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616370344?lang=zh_cn&edition=full","pubTime":"2026-03-03 19:30","pubTimestamp":1772537441,"startTime":"0","endTime":"0","summary":"每经AI快讯，诺诚健华（688428.SH）3月3日在投资者互动平台表示，根据公司业绩预告，公司预计2025年度首次实现扭亏为盈，预计2025年实现营业总收入人民币23.65亿元左右，与上年同期相比增长134%左右，归属于母公司所有者的净利润为6.33亿元左右。公司对于未来包括奥布替尼在内的药品销售、管线进展及商业化合作充满信心。更重要的是，公司的增长逻辑并非依赖单一产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603033660525335.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603033660525335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK4080","BK4231","688428","BK1161","09969","BK1574","ADC"],"gpt_icon":0},{"id":"2616867317","title":"3月3日诺诚健华跌5.51%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616867317","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616867317?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:38","pubTimestamp":1772527102,"startTime":"0","endTime":"0","summary":"证券之星消息，3月3日诺诚健华跌5.51%，收盘报21.43元，换手率3.25%，成交量8.73万手，成交额1.91亿元。重仓诺诚健华的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，增持评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共13家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.77亿元，最新净值2.8503，较上一交易日下跌2.12%，近一年上涨19.32%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300029072.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK1161","BK0239","BK1574","688428"],"gpt_icon":0},{"id":"1161002585","title":"诺诚健华新一代TRK抑制剂Zurletrectinib获中国优先审评资格 将用于儿童实体瘤治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1161002585","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161002585?lang=zh_cn&edition=full","pubTime":"2026-03-02 10:05","pubTimestamp":1772417150,"startTime":"0","endTime":"0","summary":"诺诚健华医药有限公司宣布，其自主研发的新一代TRK抑制剂Zurletrectinib已获得中国国家药品监督管理局授予优先审评资格。该药物将专门用于儿童实体瘤患者的治疗方案，标志着公司在肿瘤创新药研发领域取得重要进展。\n此次优先审评资格的获得，将显著加速Zurletrectinib在中国的上市进程。作为针对特定基因突变的新型靶向药物，该产品有望为儿童实体瘤患者提供更精准的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688428"],"gpt_icon":0},{"id":"2614840998","title":"港股异动 | 诺诚健华(09969)尾盘涨超4% BCL2抑制剂联合奥布替尼3期临床完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2614840998","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614840998?lang=zh_cn&edition=full","pubTime":"2026-02-27 15:36","pubTimestamp":1772177779,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华尾盘涨超4%，截至发稿，涨3.96%，报12.08港元，成交额4471.55万港元。消息面上，诺诚健华宣布，公司自主研发的新型BCL2抑制剂mesutoclax联合BTK抑制剂奥布替尼一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的注册性3期临床试验已经完成患者入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688428","09969","BK1161","BK4585","BK1574","VXUS","BK4588","BK0239","VT"],"gpt_icon":0},{"id":"2614062136","title":"诺诚健华新型BCL2抑制剂Mesutoclax联合奥布替尼一线治疗CLL/SLL的注册性III期临床试验完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2614062136","media":"人民财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614062136?lang=zh_cn&edition=full","pubTime":"2026-02-26 10:40","pubTimestamp":1772073636,"startTime":"0","endTime":"0","summary":"人民财讯2月26日电，诺诚健华2月26日宣布，公司自主研发的新型BCL2抑制剂mesutoclax（ICP-248）联合BTK抑制剂奥布替尼一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）的注册性III期临床试验已经完成患者入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602263655089844.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688428","III","BK4134","BK1161","09969","BK1574","BK0239"],"gpt_icon":0},{"id":"1153892075","title":"诺诚健华宣布新型Tyk2抑制剂索菲西替尼在华治疗慢性自发性荨麻疹II/III期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1153892075","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153892075?lang=zh_cn&edition=full","pubTime":"2026-02-13 10:23","pubTimestamp":1770949396,"startTime":"0","endTime":"0","summary":"诺诚健华今日宣布，其自主研发的新型Tyk2抑制剂索菲西替尼（Soficitinib）针对慢性自发性荨麻疹适应症，已在中国启动II/III期临床试验并完成首例患者给药。\n该临床试验旨在评估索菲西替尼在慢性自发性荨麻疹患者中的疗效与安全性。作为一款高选择性Tyk2抑制剂，索菲西替尼通过精准调控JAK-STAT信号通路，有望为患者提供新的治疗选择。\n此次临床进展标志着诺诚健华在自身免疫疾病领域创新药研发取得重要突破。公司将持续推进该药物的临床开发进程，加速潜在创新疗法的上市步伐。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK0239"],"gpt_icon":0},{"id":"2610187799","title":"诺诚健华携手清华大学获批北京重点实验室","url":"https://stock-news.laohu8.com/highlight/detail?id=2610187799","media":"中国网财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610187799?lang=zh_cn&edition=full","pubTime":"2026-02-12 13:33","pubTimestamp":1770874412,"startTime":"0","endTime":"0","summary":"中国网财经2月12日讯近日，北京市科学技术委员会、中关村科技园区管理委员会公布了2025年北京市重点实验室认定名单。由清华大学作为依托单位，诺诚健华作为共建单位联合申报的“口服药物智能设计与递送北京市重点实验室”成功获批。“口服药物智能设计与递送北京市重点实验室”是合作双方长期深耕、协同创新的重要里程碑，标志着合作从项目层面迈向体系化、平台化的新阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602123649065380.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602123649065380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK1574","688428","BK1161","09969"],"gpt_icon":0},{"id":"2609258485","title":"每周股票复盘：诺诚健华（688428）1月31日股本无变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2609258485","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609258485?lang=zh_cn&edition=full","pubTime":"2026-02-08 01:39","pubTimestamp":1770485948,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，诺诚健华报收于24.02元，较上周的21.4元上涨12.24%。本周，诺诚健华2月6日盘中最高价报24.58元。诺诚健华当前最新总市值423.87亿元，在化学制药板块市值排名12/150，在两市A股市值排名477/5186。本周关注点公司公告汇总：诺诚健华截至2026年1月31日已发行股份为1,496,284,235股，库存股2,486,000股，无增减变动。公司公告汇总诺诚健华医药有限公司截至2026年1月31日，法定注册资本为250亿股普通股，每股面值0.000002美元，总法定股本5万美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","BK1161","09969","688428"],"gpt_icon":0},{"id":"2609563163","title":"2月6日诺诚健华涨10.13%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2609563163","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609563163?lang=zh_cn&edition=full","pubTime":"2026-02-06 16:32","pubTimestamp":1770366770,"startTime":"0","endTime":"0","summary":"证券之星消息，2月6日诺诚健华涨10.13%，收盘报24.02元，换手率8.82%，成交量23.67万手，成交额5.56亿元。重仓诺诚健华的前十大公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级1家，增持评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共13家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.77亿元，最新净值2.9402，较上一交易日上涨0.56%，近一年上涨35.36%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600027021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688428","BK1161","09969","BK1574"],"gpt_icon":0},{"id":"2609346495","title":"港股异动 | 诺诚健华(09969)早盘涨超4% 公司首次实现扭亏为盈 核心产品奥布替尼贡献显著增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2609346495","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609346495?lang=zh_cn&edition=full","pubTime":"2026-02-05 10:50","pubTimestamp":1770259821,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华早盘涨超4%，截至发稿，涨3.95%，报11.83港元，成交额3869.91万港元。消息面上，诺诚健华此前发布业绩预告，预计2025年实现收入23.7亿元，同比增长约134%；预计2025年归母净利润首次扭亏为盈，达6.3亿元左右。核心产品奥布替尼贡献显著增量，2025年5月坦昔妥单抗获批上市后进一步丰富药品收入来源。值得注意的是，诺诚健华宣布，公司自主研发的新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验已完成患者入组，总共入组383例患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","09969","BK1574","BK0239","BK4585","BK1161","BK4588","VT","688428"],"gpt_icon":0},{"id":"2608398843","title":"诺诚健华（688428）披露证券变动月报表，2月4日股价上涨1.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608398843","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608398843?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:26","pubTimestamp":1770215179,"startTime":"0","endTime":"0","summary":"截至2026年2月4日收盘，诺诚健华报收于21.51元，较前一交易日上涨1.8%，最新总市值为379.57亿元。该股当日开盘21.06元，最高21.72元，最低20.9元，成交额达1.91亿元，换手率为3.34%。近日，诺诚健华医药有限公司发布证券变动月报表。公司确认已符合香港联交所规定的公众持股量要求。此外，公告提及2023年及2024年人民币股份激励计划的相关安排，涉及部分限制性股票失效情况，但本月未因相关协议导致股份变动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400041567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","161027","BK1161","09969","688428"],"gpt_icon":0},{"id":"2608036200","title":"诺诚健华：公司预计2025年度首次实现扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2608036200","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608036200?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:38","pubTimestamp":1770212317,"startTime":"0","endTime":"0","summary":"证券日报网讯2月4日，诺诚健华在互动平台回答投资者提问时表示，公司在管线推进、商业化拓展等方面均按照计划及目标顺利推进，经营一切正常，不存在经营困境。根据公司业绩预告，公司预计2025年度首次实现扭亏为盈，预计2025年实现营业总收入人民币23.65亿元左右，与上年同期相比增长134%左右，归属于母公司所有者的净利润为6.33亿元左右。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602043641731339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK1574","688428","BK1161","09969"],"gpt_icon":0},{"id":"2608880406","title":"诺诚健华新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2608880406","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608880406?lang=zh_cn&edition=full","pubTime":"2026-02-02 08:50","pubTimestamp":1769993437,"startTime":"0","endTime":"0","summary":"每经AI快讯，2月2日，诺诚健华官微宣布，公司自主研发的新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验已完成患者入组，总共入组383例患者。这一里程碑标志着ICP-488治疗银屑病取得重大临床进展，有望为银屑病患者带来新的口服治疗选择。这项临床试验为多中心、随机、双盲、安慰剂对照，旨在评价ICP-488单药治疗中重度斑块状银屑病成人患者的有效性和安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602023638037294.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638037294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688428","BK4134","BK1161","09969","III","BK1574"],"gpt_icon":0},{"id":"2608072758","title":"每周股票复盘：诺诚健华（688428）预计2025年净利6.33亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2608072758","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608072758?lang=zh_cn&edition=full","pubTime":"2026-02-01 01:55","pubTimestamp":1769882111,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，诺诚健华报收于21.4元，较上周的20.29元上涨5.47%。本周，诺诚健华1月30日盘中最高价报22.5元。诺诚健华当前最新总市值377.63亿元，在化学制药板块市值排名12/150，在两市A股市值排名553/5184。业绩披露要点诺诚健华发布业绩预告，预计2025年全年归属净利润盈利约6.33亿元。公司公告汇总诺诚健华医药有限公司预计2025年实现营业总收入约23.65亿元，同比增长134%左右。扣除非经常性损益后的净利润为5.34亿元左右，同比增加9.74亿元左右。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","09969","BK0239","688428","BK1574"],"gpt_icon":0},{"id":"2607628066","title":"诺诚健华(09969.HK)高开逾13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607628066","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607628066?lang=zh_cn&edition=full","pubTime":"2026-01-30 09:36","pubTimestamp":1769736987,"startTime":"0","endTime":"0","summary":"每经AI快讯，诺诚健华(09969.HK)高开逾13%，截至发稿，涨13.6%，报13.2港元，成交额1099.56万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601303636358961.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303636358961.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","BK0239","688428","09969"],"gpt_icon":0},{"id":"2607050701","title":"股市必读：诺诚健华（688428）预计2025年全年扣非后净利润盈利约5.34亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607050701","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607050701?lang=zh_cn&edition=full","pubTime":"2026-01-30 08:06","pubTimestamp":1769731601,"startTime":"0","endTime":"0","summary":"业绩预告诺诚健华发布业绩预告，预计2025年全年扣非后净利润盈利约5.34亿元；预计2025年全年归属净利润盈利约6.33亿元。诺诚健华医药有限公司2025年年度业绩预告诺诚健华医药有限公司预计2025年实现营业总收入约23.65亿元，同比增长134%左右；预计2025年度归属于母公司所有者的净利润为6.33亿元左右，同比增加10.74亿元左右，首次实现扭亏为盈；扣除非经常性损益后的净利润为5.34亿元左右，同比增加9.74亿元左右。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260130/31984716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["09969","688428"],"gpt_icon":0},{"id":"2607361810","title":"诺诚健华（688428）披露2025年年度业绩预告，1月29日股价下跌1.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607361810","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607361810?lang=zh_cn&edition=full","pubTime":"2026-01-29 22:57","pubTimestamp":1769698630,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，诺诚健华报收于20.15元，较前一交易日下跌1.18%，最新总市值为355.58亿元。该股当日开盘20.35元，最高20.74元，最低19.96元，成交额达1.31亿元，换手率为2.41%。近日，诺诚健华医药有限公司发布2025年年度业绩预告。本次业绩预告未经注册会计师审计。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900044032.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","09969","688428","BK0239","BK1574"],"gpt_icon":0},{"id":"2607384830","title":"诺诚健华：公司未来会持续推进全球化战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2607384830","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607384830?lang=zh_cn&edition=full","pubTime":"2026-01-29 21:50","pubTimestamp":1769694643,"startTime":"0","endTime":"0","summary":"证券日报网讯1月29日，诺诚健华在互动平台回答投资者提问时表示，公司与Zenas交易不仅为公司带来了实质性的即期财务收益，进一步增强了公司的现金储备与资产结构，里程碑付款可以为公司带来可持续的现金流与长期收益，此次合作也将有助于最大化奥布替尼在全球范围内的临床与商业价值，使产品能够更快惠及全球患者，也充分体现了公司创新资产的国际竞争力与长期商业潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601293635632811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK1574","688428","BK1161","09969"],"gpt_icon":0},{"id":"2607038418","title":"诺诚健华：二级市场股价受多种因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2607038418","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607038418?lang=zh_cn&edition=full","pubTime":"2026-01-29 21:50","pubTimestamp":1769694642,"startTime":"0","endTime":"0","summary":"诺诚健华：二级市场股价受多种因素影响","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601293635632188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","BK1574","688428","BK1161","BK0239"],"gpt_icon":0},{"id":"2607704567","title":"诺诚健华：预计2025年年度净利润6.33亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2607704567","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607704567?lang=zh_cn&edition=full","pubTime":"2026-01-29 16:40","pubTimestamp":1769676015,"startTime":"0","endTime":"0","summary":"每经AI快讯，1月29日，诺诚健华公告，公司预计2025年度首次实现扭亏为盈，归属于母公司所有者的净利润为6.33亿元左右，上年同期为亏损4.41亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601293635268968.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601293635268968.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688428","09969"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772762993955,"stockEarnings":[{"period":"1week","weight":-0.0592},{"period":"1month","weight":0.0308},{"period":"3month","weight":-0.1285},{"period":"6month","weight":-0.2401},{"period":"1year","weight":0.2195},{"period":"ytd","weight":0.0614}],"compareEarnings":[{"period":"1week","weight":-0.0092},{"period":"1month","weight":0.01},{"period":"3month","weight":0.0527},{"period":"6month","weight":0.0777},{"period":"1year","weight":0.2294},{"period":"ytd","weight":0.0352}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"诺诚健华医药有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"19600人(较上一季度增加1.55%)","perCapita":"13691股","listingDate":"2022-09-21","address":"Ogier Global(Cayman)Limited 89 Nexus Way Camana Bay Grand Cayma KY1-9009 Cayman Islands","registeredCapital":"0万元","survey":" 诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼、坦昔妥单抗、ICP-248、ICP-B02。公司2023年被认定为国家级专精特新“小巨人”企业。","listedPrice":11.03},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,688428,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}